Research Article
Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series
Table 2
Initial laboratory findings of patients.
| | Patient | | Case 1 | Case 2 | Case 3 | Case 4 |
| | Laboratory findings on admission | | WBC (/mm3) | 2890 | 5260 | 3980 | 4580 | | Neutrophil (%) | 66.1 | 50.7 | 83 | 85.8 | | Lymphocyte (%) | 22.5 | 35.2 | 12.3 | 7.6 | | Hemoglobin (g/dL) | 14.6 | 11.6 | 18.9 | 12.5 | | Platelets (103/mm3) | 113 | 159 | 113 | 153 | | AST (IU/L) | 28 | 28 | 32 | 55 | | ALT (IU/L) | 18 | 20 | 23 | 39 | | LDH (U/L) | 294 | 275 | 283 | 249 | | BUN (mg/dL) | 13.7 | 9.7 | 7.9 | 16.1 | | Cr (mg/dL) | 0.89 | 0.77 | 0.96 | 0.87 | | CRP (mg/dL) | 4.45 | 7.75 | 12.1 | 21.31 | | Procalcitonin (ng/mL) | 0.065 | <0.06 | <0.06 | 0.226 | | Ct value of COVID-19 RT-PCR | 36.33 | 33.97 | 24.76 | 29.65 |
|
|
WBC: white blood cells; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactate dehydrogenase; BUN: blood urea nitrogen; Cr: creatinine; CRP: C-reactive protein; Ct: cycle threshold; RT-PCR: reverse transcription-polymerase chain reaction.
|
